Meticulous Research®—a leading market research company, published a research report titled, ‘Middle East & Africa Molecular Diagnostics Market by Offering (Reagents, Kits, Systems, Software) Test Type (Lab, PoC) Technology (PCR, ISH, INAAT, Sequencing, Microarray) Application (Influenza, HPV, Oncology, Gene Testing) End User - Forecast to 2031’
According to this latest publication from Meticulous Research®, the Middle East & Africa molecular diagnostics market is projected to reach $1.16 billion by 2031, at a CAGR of 5.4% from 2024 to 2031. The growth of the Middle East & Africa molecular diagnostics market is driven by factors such as the rising prevalence of communicable and non-communicable diseases, technological advancements in molecular diagnostics, increasing investments and funding aimed at enhancing healthcare systems in the Middle East & Africa, and the rising healthcare expenditure in the region. However, inconsistencies in medical device regulations across the Middle East & Africa and the high costs of molecular diagnostic tests restrain the market’s growth.
Emerging medical and wellness tourism in the UAE and a growing focus on companion diagnostics are expected to create market growth opportunities. However, the shortage of skilled professionals poses a significant challenge to the growth of this market.
Key Players
The key players profiled in the Middle East & Africa molecular diagnostics market report are AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
The Middle East & Africa molecular diagnostics market is segmented by Offering (Kits & Reagents, Instruments, Software & Services), Test Type (Laboratory Tests and Point-of-Care [POC] Tests), Technology (Polymerase Chain Reaction [PCR], In Situ Hybridization [ISH], Isothermal Nucleic Acid Amplification Technology [INAAT], Microarrays, Sequencing, Mass Spectrometry, and Other Technologies), Application (Infectious Diseases [Respiratory Diseases, Hepatitis, HIV, Chlamydia Trachomatis/Neisseria Gonorrhoeae, Human Papillomavirus {HPV}, Healthcare-Associated Infections {HAIs}, and Other Infectious Diseases], Oncology [Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Lymphoma, Leukemia, Cervical Cancer, and Other Cancer Types], Genetic Testing, Neurological Diseases, Cardiovascular Diseases, and Other Applications), End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Other End Users), and geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.
Among the offerings studied in this report, in 2024, the kits and reagents segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the wide availability of a diverse range of diagnostic reagents & consumables and the growing awareness regarding the importance of early disease diagnosis. For instance, in September 2023, the World Health Organization (WHO) Regional Office for Africa, along with the support of F. Hoffmann-La Roche Ltd. (Switzerland), launched an initiative in Cote d’Ivoire, Kenya, and Zimbabwe to provide health promotion, detection, screening, and early diagnosis and treatment of breast and cervical cancer. This initiative was aimed at providing an integrated and holistic system of healthcare that will contribute to addressing the burden of breast and cervical cancer in the African region.
Among the test types studied in this report, in 2024, the laboratory test segments is expected to account for the largest share of the market. The large market share of this segment can be attributed to the substantial number of laboratory tests conducted in hospitals and laboratories due to the high accuracy of the test results. Furthermore, the expansion and enhancement of diagnostic laboratory networks in the region also contribute to the segment's significant market share. For instance, in December 2021, 54gene (Nigeria) launched a chain of diagnostic labs named 7RiverLabs. These labs are equipped with state-of-the-art technology, offering world-class, cost-effective, speedy, reliable, and advanced molecular diagnostics to healthcare providers and patients.
Among the technologies studied in this report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the market. The large market share of this segment can be attributed to the high specificity and sensitivity of the instrument, along with technological advancements in PCR technology. Additionally, the improved PCR testing capabilities in laboratories and the introduction of new products during the COVID-19 pandemic to address the growing burden contribute to the growth of this segment. For instance, in February 2022, F. Hoffmann-La Roche Ltd. (Switzerland) expanded its COVID-19 PCR portfolio with the introduction of the cobas 5800 system in countries accepting the CE mark. This expansion includes the cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests, offering standardized performance and efficiencies in addressing various molecular laboratory testing needs across low, medium, and high volumes.
Among the applications studied in this report, in 2024, the infectious diseases segment is expected to account for the largest share of the market. The large market share of this segment can be attributed to the growing prevalence of infectious diseases and the rise in funding allocated for the development of new diagnostic tools for infectious diseases. According to the World Health Organization (WHO), in 2022, there were a total of 249 million cases of malaria worldwide, with the African region accounting for 94% of these cases. The rising incidence of such infections drives the demand for rapid, user-friendly, and cost-effective infectious disease testing tools.
Among the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the market. The large market share of this segment can be attributed to the increased number of hospitalizations due to various diseases that necessitate molecular diagnosis. Additionally, the proliferation of hospitals and clinics in emerging countries contributes to the growing utilization of molecular diagnostic products. The expansion of hospitals in the Middle East & Africa further drives the demand for molecular diagnostic tests. For instance, in April 2023, Burjeel Holdings (UAE.) partnered with OncoHelix, Inc. (U.S.) to establish a state-of-the-art laboratory in Abu Dhabi (UAE), offering advanced molecular diagnostics, cellular, and immunological profile testing for patients in the UAE.
Among the countries studied in this report, in 2024, Saudi Arabia is expected to account for the largest share of the market. The large market share of this segment can be attributed to factors such as the high disease burden of both communicable and non-communicable diseases, the widespread adoption of molecular diagnostics in laboratory tests, ongoing improvements in the healthcare infrastructure, and rising healthcare expenditure.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5791
Key questions answered in the report:
• Which are the high-growth market segments in terms of molecular diagnostics in the Middle East & Africa by offering, test type, technology, application, end user, and geography?
• What was the historical market for molecular diagnostics across the Middle East & Africa?
• What are the market forecasts and estimates for the period 2024–2031?
• What are the major drivers, restraints, opportunities, and challenges in the Middle East & Africa molecular diagnostics market?
• Who are the major players in the Middle East & Africa molecular diagnostics market?
• What is the competitive landscape like, and who are the market leaders in the Middle East & Africa molecular diagnostics market?
• What are the recent developments in the Middle East & Africa molecular diagnostics market?
• What are the different strategies adopted by the major players in the Middle East & Africa molecular diagnostics market?
• What are the geographical trends and high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research